Solstice Closes $18M Series A; Raises Stakes in RNAi Delivery
By Jennifer Boggs
Monday, January 7, 2013
The promise of RNAi the idea that specific genes can be pinpointed and silenced to treat disease has loomed large on biopharma's radar for the past decade, even netting a 2006 Nobel to RNAi discoverers Craig Mello and Andrew Fire.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.